<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079672</url>
  </required_header>
  <id_info>
    <org_study_id>SDCDT014/19/113</org_study_id>
    <nct_id>NCT05079672</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dexmedetomidine in the Analgesic Prophylaxis , in Patients Undergoing Cardiovascular Surgery</brief_title>
  <official_title>Efficacy and Safety of Dexmedetomidine in the Analgesic Prophylaxis , in Patients Undergoing Cardiovascular Surgery: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Paraíba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pain is one of the complications after cardiothoracic surgeries . It can delay&#xD;
      patients´recovery and may increase patients´morbity and mortality. This study intends to&#xD;
      evaluate Dexmedetomidine, a highly selective α- 2 receptor agonist, that is currently applied&#xD;
      safely and efficiently in intraoperative cardiac surgery. It has analgesic, sedative,&#xD;
      anxiolytic and sympatholytic properties, without respiratory- depressant effect. The aim of&#xD;
      this study is to investigate whether the intraoperative use of dexmedetomidine is better than&#xD;
      the standard analgesia used in the intraoperative period to reduce pain and the consequences&#xD;
      of it.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is a prospective, double-blinded and randomized clinical trial. Eligible&#xD;
      participants are assigned in a 1:1 ratio to either the intervention group (Group&#xD;
      Dexmedetomidine) or control group (Group Saline 0,9%), after written informed consent to be&#xD;
      obtained. The patients will undergo elective cardiac surgery, with extracorporeal&#xD;
      circulation.&#xD;
&#xD;
      In the operating room, patients will be monitored for pulse oximetry, invasive blood&#xD;
      pressure, electrocardiograms, capnography, central venous pressure and nasopharyngeal&#xD;
      temperature probe. Induction of anesthesia is performed with intravenous midazolam, fentanyl,&#xD;
      etomidate and neuromuscular blocking agent. Anesthesia is maintained with sevoflurane.&#xD;
      Dexmedetomidine, at the rate of 0,3μg/ kg/h, or placebo will be infused from the initiation&#xD;
      of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.&#xD;
      Placebo is a 0,9% saline. The follow up of the assessment of the groups will extend to the&#xD;
      postoperative ICU, where data will be collected, during the first 24 hours after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">October 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain 24 hours after cardiac surgery.</measure>
    <time_frame>24 hours after the cardiac surgery.</time_frame>
    <description>The assessment of pain intensity, in patients with self- reporting, will be done by: Numeric Rating Scale (NRS) 0- 10. Possible score range from 0 (no pain) to 10 (worst pain ever ). The assessment of pain intensity, in patients on mechanical ventilation, will be done by: Behavioral Pain Scale, through facial expression (score 1-4), upper limb movement (score 1-5) and compliance with mechanical ventilation (score 1-3). Possible score range from 3 (no pain) to 12 (maximum pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption.</measure>
    <time_frame>During the first 24 hours.</time_frame>
    <description>Opioid used for the pain control. This will be noted in the medical record.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time from the end of surgery to extubation.</measure>
    <time_frame>During the first 24 hours.</time_frame>
    <description>This interval will be observed if the patient is not extubated at the end of the surgery. This will be noted in the medical record.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding.</measure>
    <time_frame>During the first 24 hours.</time_frame>
    <description>Bleeding after the surgery. This will be noted in the medical record.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac arrhythmias.</measure>
    <time_frame>During the first 24 hours.</time_frame>
    <description>Occurrence of cardiac arrhythmias. This will be noted in the medical record.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum creatinine and urea.</measure>
    <time_frame>During the first 24 hours.</time_frame>
    <description>The serum level of creatinine and urea will be observed, in the usual daily measure. This will be noted in the medical record.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Cardiopathy</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Valve Heart Disease</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive Dexmedetomidine, at the rate of 0,3μg/ kg/h, in continuous intravenous infusion from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 0,9% Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient will receive a 0,9% saline, in continuous intravenous infusion, from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine injectable solution, at the rate of 0,3μg/ kg/h, will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.</description>
    <arm_group_label>Group Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0,9% Saline</intervention_name>
    <description>Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.</description>
    <arm_group_label>Group 0,9% Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients at least 18 years old and who are undergoing cardiac procedures (coronary&#xD;
             artery bypass, valve replacement or combined procedure), with cardiopulmonary by-&#xD;
             pass.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital heart disease&#xD;
&#xD;
          -  Infective endocarditis&#xD;
&#xD;
          -  Acute myocardial infarction (&lt;two weeks)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Left ventricle ejection fraction &lt; 40%&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Emergent procedure&#xD;
&#xD;
          -  Use of vasopressor and/or inotrope, in the preoperative&#xD;
&#xD;
          -  Liver disfunction&#xD;
&#xD;
          -  Renal replacement therapy&#xD;
&#xD;
          -  Nephrectomy&#xD;
&#xD;
          -  Previous renal transplantation&#xD;
&#xD;
          -  Patients who are participating in another clinical research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiz Antônio Machado César</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luiz Antônio Machado César</last_name>
    <phone>551126617585</phone>
    <email>cappesq.adm@hc.fm.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lígia Ferreira dos santos</last_name>
    <phone>558399189-6525</phone>
    <email>ligiafs1@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nova Esperança University Hospital</name>
      <address>
        <city>João Pessoa</city>
        <state>Paraíba</state>
        <zip>58.015-345</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Antônio Machado César</last_name>
      <phone>551126617585</phone>
      <email>cappesq.adm@hc.fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Lígia Ferreira dos santos</last_name>
      <phone>5583991896525</phone>
      <email>ligiafs1@usp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Luiz Antônio Machado César</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lígia Ferreira dos Santos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Institute (InCor), Univ. of Sao Paulo Medical School</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz A Machado Cesar, Phd, MD</last_name>
      <phone>551130695387</phone>
      <email>luiz.cesar@incor.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Bruno M Mioto, MD</last_name>
      <phone>551130695437</phone>
      <email>brunomioto@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno M Mioto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel A Moretti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Taratsouchi, nutricionist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reynaldo V Amato, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vera Lucia Tuda, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Kundra S, Taneja S, Choudhary AK, Katyal S, Garg I, Roy R. Effect of a low-dose dexmedetomidine infusion on intraoperative hemodynamics, anesthetic requirements and recovery profile in patients undergoing lumbar spine surgery. J Anaesthesiol Clin Pharmacol. 2019 Apr-Jun;35(2):248-253. doi: 10.4103/joacp.JOACP_338_18.</citation>
    <PMID>31303717</PMID>
  </reference>
  <reference>
    <citation>Bielka K, Kuchyn I, Babych V, Martycshenko K, Inozemtsev O. Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic сholecystectomy: a randomized controlled study. BMC Anesthesiol. 2018 Apr 20;18(1):44. doi: 10.1186/s12871-018-0508-6.</citation>
    <PMID>29678158</PMID>
  </reference>
  <reference>
    <citation>Talke P, Chen R, Thomas B, Aggarwall A, Gottlieb A, Thorborg P, Heard S, Cheung A, Son SL, Kallio A. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg. 2000 Apr;90(4):834-9.</citation>
    <PMID>10735784</PMID>
  </reference>
  <reference>
    <citation>Aho MS, Erkola OA, Scheinin H, Lehtinen AM, Korttila KT. Effect of intravenously administered dexmedetomidine on pain after laparoscopic tubal ligation. Anesth Analg. 1991 Aug;73(2):112-8.</citation>
    <PMID>1854025</PMID>
  </reference>
  <reference>
    <citation>Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol. 2008 Aug;21(4):457-61. doi: 10.1097/ACO.0b013e328305e3ef. Review.</citation>
    <PMID>18660652</PMID>
  </reference>
  <reference>
    <citation>Kotfis K, Strzelbicka M, Zegan-Barańska M, Safranow K, Brykczyński M, Żukowski M, Ely EW; POL-BPS Study Group. Validation of the behavioral pain scale to assess pain intensity in adult, intubated postcardiac surgery patients: A cohort observational study - POL-BPS. Medicine (Baltimore). 2018 Sep;97(38):e12443. doi: 10.1097/MD.0000000000012443.</citation>
    <PMID>30235728</PMID>
  </reference>
  <reference>
    <citation>Habibi V, Kiabi FH, Sharifi H. The Effect of Dexmedetomidine on the Acute Pain After Cardiothoracic Surgeries: A Systematic Review. Braz J Cardiovasc Surg. 2018 Jul-Aug;33(4):404-417. doi: 10.21470/1678-9741-2017-0253.</citation>
    <PMID>30184039</PMID>
  </reference>
  <reference>
    <citation>Hall R. Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. J Cardiothorac Vasc Anesth. 2013 Oct;27(5):983-1033. doi: 10.1053/j.jvca.2012.09.013. Epub 2012 Dec 29. Review.</citation>
    <PMID>23276596</PMID>
  </reference>
  <reference>
    <citation>Brandão PG, Lobo FR, Ramin SL, Sakr Y, Machado MN, Lobo SM. Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study. Braz J Cardiovasc Surg. 2016 May-Jun;31(3):213-218. doi: 10.5935/1678-9741.20160043.</citation>
    <PMID>27737403</PMID>
  </reference>
  <reference>
    <citation>Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY; MAC Study Group. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010 Jan 1;110(1):47-56. doi: 10.1213/ane.0b013e3181ae0856. Epub 2009 Aug 27.</citation>
    <PMID>19713256</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 3, 2021</study_first_submitted>
  <study_first_submitted_qc>October 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Luiz Antonio M. Cesar</investigator_full_name>
    <investigator_title>Associated Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This will be decided, after data collection stars.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

